Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Eric Wu

Concepts (357)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
28
2022
395
3.930
 Why?
Everolimus
10
2016
68
2.530
 Why?
Health Resources
8
2022
120
2.380
 Why?
Cost of Illness
12
2022
288
2.120
 Why?
Receptor, ErbB-2
9
2016
336
1.540
 Why?
Breast Neoplasms
12
2016
2139
1.420
 Why?
Hyperkalemia
2
2020
26
1.250
 Why?
Medication Adherence
6
2016
573
1.230
 Why?
Receptors, Estrogen
3
2015
428
1.200
 Why?
Receptors, Antigen, T-Cell
4
2021
701
1.170
 Why?
Immunotherapy, Adoptive
2
2020
295
1.090
 Why?
Health Expenditures
6
2020
184
1.050
 Why?
Practice Patterns, Physicians'
4
2016
1266
1.020
 Why?
Health Services
6
2016
103
0.970
 Why?
United States
39
2022
13876
0.870
 Why?
Receptors, Progesterone
2
2015
345
0.850
 Why?
Models, Economic
2
2020
55
0.840
 Why?
Hepatitis C, Chronic
2
2015
153
0.840
 Why?
Antifungal Agents
4
2017
125
0.800
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
113
0.780
 Why?
Middle Aged
52
2020
30893
0.750
 Why?
Antineoplastic Agents
9
2016
2058
0.750
 Why?
Hospital Costs
3
2020
116
0.720
 Why?
Gout
2
2012
36
0.710
 Why?
Retrospective Studies
31
2022
14460
0.700
 Why?
Aged
38
2022
21971
0.700
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
280
0.680
 Why?
Nocturia
1
2019
8
0.670
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2016
1565
0.670
 Why?
Kaplan-Meier Estimate
10
2017
857
0.620
 Why?
Proportional Hazards Models
12
2017
1208
0.620
 Why?
Female
63
2021
68127
0.610
 Why?
Cost-Benefit Analysis
12
2022
581
0.610
 Why?
Hospitalization
13
2021
2071
0.610
 Why?
Depressive Disorder, Major
3
2011
347
0.590
 Why?
Candida
2
2017
35
0.580
 Why?
Nutrition Surveys
1
2019
262
0.580
 Why?
Proline
2
2015
78
0.580
 Why?
Fluconazole
1
2017
18
0.560
 Why?
Candidemia
1
2017
9
0.560
 Why?
Humans
80
2022
128524
0.560
 Why?
Myocardial Perfusion Imaging
1
2017
36
0.550
 Why?
Male
53
2021
62883
0.550
 Why?
Medicare
7
2022
718
0.540
 Why?
Cardiologists
1
2017
46
0.540
 Why?
Tomography, Emission-Computed, Single-Photon
1
2017
78
0.540
 Why?
Fees, Pharmaceutical
3
2016
13
0.540
 Why?
Prevalence
10
2020
2549
0.530
 Why?
Oligopeptides
2
2015
257
0.530
 Why?
Adult
41
2022
35315
0.520
 Why?
Thrombolytic Therapy
1
2017
132
0.520
 Why?
Insurance Claim Review
8
2017
72
0.510
 Why?
Biological Therapy
1
2016
29
0.510
 Why?
Antirheumatic Agents
2
2016
282
0.510
 Why?
Citalopram
3
2011
34
0.500
 Why?
Renal Insufficiency, Chronic
2
2020
564
0.490
 Why?
Tissue Plasminogen Activator
1
2017
220
0.490
 Why?
Drug Eruptions
1
2015
26
0.490
 Why?
Psoriasis
3
2012
91
0.470
 Why?
Fibrinolytic Agents
1
2017
249
0.470
 Why?
Databases, Factual
8
2016
1268
0.460
 Why?
Hypoglycemic Agents
2
2015
1214
0.460
 Why?
Comparative Effectiveness Research
2
2012
151
0.460
 Why?
Diphosphonates
2
2012
58
0.460
 Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
343
0.450
 Why?
Delivery of Health Care
2
2019
892
0.450
 Why?
Physicians, Primary Care
1
2017
227
0.450
 Why?
Brain Ischemia
1
2017
304
0.440
 Why?
Anemia
1
2015
156
0.440
 Why?
Imidazoles
2
2012
228
0.430
 Why?
Liver Neoplasms
2
2015
640
0.430
 Why?
Dextroamphetamine
1
2012
3
0.400
 Why?
Antiviral Agents
2
2015
704
0.400
 Why?
Methylphenidate
1
2012
37
0.390
 Why?
Drug Delivery Systems
1
2015
326
0.380
 Why?
Drug Costs
6
2015
103
0.380
 Why?
Aged, 80 and over
11
2020
7040
0.380
 Why?
Referral and Consultation
1
2017
727
0.370
 Why?
Schizophrenia
2
2006
429
0.370
 Why?
Pulmonary Embolism
1
2014
208
0.370
 Why?
Neoplasm Metastasis
6
2016
608
0.370
 Why?
Fumarates
1
2011
10
0.360
 Why?
Drugs, Generic
1
2011
17
0.360
 Why?
Hypertension
4
2018
1238
0.360
 Why?
Drug Substitution
1
2011
52
0.360
 Why?
Central Nervous System Stimulants
1
2012
156
0.350
 Why?
Bone Diseases
1
2011
61
0.350
 Why?
Postmenopause
4
2016
370
0.350
 Why?
Stroke
2
2017
1064
0.340
 Why?
Angiotensin Receptor Antagonists
1
2011
90
0.340
 Why?
Amides
1
2011
91
0.340
 Why?
Venous Thromboembolism
1
2014
274
0.340
 Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
201
0.330
 Why?
Multiple Myeloma
1
2011
123
0.330
 Why?
Crohn Disease
5
2012
211
0.330
 Why?
Arthritis, Rheumatoid
2
2016
1108
0.330
 Why?
Diabetes Mellitus
1
2018
1001
0.320
 Why?
Anticoagulants
1
2014
613
0.320
 Why?
Insurance, Health
3
2011
271
0.320
 Why?
Sick Leave
2
2007
14
0.320
 Why?
Diabetes Mellitus, Type 2
2
2015
2430
0.320
 Why?
Hyperuricemia
1
2009
45
0.320
 Why?
Antibodies, Monoclonal
6
2011
1355
0.310
 Why?
Disease-Free Survival
5
2016
656
0.310
 Why?
Antineoplastic Agents, Hormonal
3
2016
158
0.300
 Why?
Costs and Cost Analysis
7
2019
208
0.300
 Why?
Heart Failure
2
2020
2150
0.300
 Why?
Risk Factors
12
2017
9727
0.300
 Why?
Patient Acceptance of Health Care
7
2021
764
0.290
 Why?
Attention Deficit Disorder with Hyperactivity
1
2012
398
0.290
 Why?
Absenteeism
2
2005
49
0.290
 Why?
Quality of Life
8
2021
2680
0.290
 Why?
Uric Acid
1
2009
161
0.290
 Why?
Comorbidity
8
2014
1540
0.290
 Why?
Insurance Claim Reporting
2
2007
23
0.280
 Why?
Neoplasm Recurrence, Local
2
2015
957
0.280
 Why?
Physicians
1
2015
860
0.270
 Why?
Hypoglycemia
1
2012
426
0.270
 Why?
Insulin
2
2015
2318
0.270
 Why?
Head and Neck Neoplasms
1
2012
534
0.270
 Why?
Health Status Indicators
1
2007
168
0.260
 Why?
Triazoles
3
2016
151
0.260
 Why?
Pentosan Sulfuric Polyester
1
2006
1
0.260
 Why?
Economics, Pharmaceutical
1
2006
10
0.260
 Why?
Cystitis, Interstitial
1
2006
16
0.260
 Why?
Drug Resistance, Fungal
2
2017
9
0.250
 Why?
Young Adult
12
2020
12320
0.250
 Why?
Endometriosis
2
2017
48
0.250
 Why?
Urinary Incontinence
1
2005
63
0.230
 Why?
Immunoglobulin G
1
2008
837
0.230
 Why?
Prostatic Neoplasms
2
2012
1010
0.230
 Why?
Recurrence
3
2020
1001
0.220
 Why?
Treatment Outcome
12
2017
10163
0.210
 Why?
Psychotic Disorders
1
2005
153
0.210
 Why?
Drug Therapy, Combination
4
2015
1009
0.210
 Why?
Antibodies, Monoclonal, Humanized
7
2012
759
0.200
 Why?
Population Surveillance
1
2005
427
0.200
 Why?
Anti-Inflammatory Agents
3
2011
469
0.190
 Why?
Giant Cell Tumor of Tendon Sheath
1
2021
5
0.190
 Why?
Bone Density Conservation Agents
2
2012
73
0.190
 Why?
Gout Suppressants
2
2012
20
0.180
 Why?
Gastritis
1
2022
97
0.180
 Why?
Biological Products
2
2016
200
0.180
 Why?
Enteritis
1
2022
94
0.180
 Why?
Hemophilia B
1
2021
43
0.180
 Why?
Tumor Necrosis Factor-alpha
4
2009
1190
0.180
 Why?
Adolescent
17
2017
20213
0.180
 Why?
Hemophilia A
1
2021
75
0.170
 Why?
Adenocarcinoma
1
2007
888
0.170
 Why?
Voriconazole
2
2016
19
0.170
 Why?
National Health Programs
1
2019
18
0.170
 Why?
Technology Assessment, Biomedical
1
2019
29
0.170
 Why?
Eosinophilia
1
2022
205
0.170
 Why?
Regression Analysis
4
2012
983
0.160
 Why?
Genetic Therapy
1
2021
293
0.160
 Why?
Myelodysplastic Syndromes
1
2021
129
0.160
 Why?
Microbial Sensitivity Tests
2
2017
335
0.150
 Why?
Aging
1
2009
1770
0.150
 Why?
Nitriles
2
2016
160
0.150
 Why?
Treatment Failure
2
2017
342
0.150
 Why?
Idiopathic Pulmonary Fibrosis
2
2015
628
0.150
 Why?
Vital Capacity
2
2015
289
0.150
 Why?
Polystyrenes
1
2018
38
0.150
 Why?
Overweight
1
2022
525
0.140
 Why?
4-Aminopyridine
1
2017
23
0.140
 Why?
Potassium
1
2018
138
0.140
 Why?
Emergency Service, Hospital
3
2014
1968
0.140
 Why?
Retreatment
1
2017
70
0.140
 Why?
Aspergillosis
1
2016
21
0.140
 Why?
Mental Disorders
1
2005
1007
0.130
 Why?
Antihypertensive Agents
2
2011
486
0.130
 Why?
Administration, Intravenous
1
2017
137
0.130
 Why?
Abiraterone Acetate
1
2016
14
0.130
 Why?
Consumer Behavior
1
2017
68
0.130
 Why?
Patient Compliance
2
2011
562
0.130
 Why?
Hysterectomy
1
2017
119
0.130
 Why?
Administrative Claims, Healthcare
1
2016
27
0.130
 Why?
Aromatase Inhibitors
1
2016
52
0.130
 Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
45
0.130
 Why?
Chronic Disease
3
2014
1701
0.130
 Why?
Capecitabine
1
2016
47
0.130
 Why?
Health Care Rationing
1
2016
58
0.130
 Why?
Ambulatory Care
3
2015
506
0.120
 Why?
Clinical Protocols
1
2017
253
0.120
 Why?
Patient Admission
1
2017
184
0.120
 Why?
Time-to-Treatment
1
2017
180
0.120
 Why?
Prednisone
1
2016
236
0.120
 Why?
Disability Evaluation
1
2017
289
0.120
 Why?
Ki-1 Antigen
1
2015
5
0.120
 Why?
International Classification of Diseases
1
2016
124
0.120
 Why?
Androstadienes
1
2015
107
0.120
 Why?
Logistic Models
2
2014
1975
0.120
 Why?
Waiting Lists
1
2017
238
0.120
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
20
0.120
 Why?
Drug Interactions
1
2016
360
0.120
 Why?
Ribavirin
1
2015
92
0.120
 Why?
California
2
2006
400
0.110
 Why?
Cross-Sectional Studies
3
2019
5040
0.110
 Why?
Drug Administration Schedule
3
2011
757
0.110
 Why?
International Normalized Ratio
1
2014
47
0.110
 Why?
Heparin, Low-Molecular-Weight
1
2014
29
0.110
 Why?
Leukemia, Myeloid, Acute
1
2021
591
0.110
 Why?
Amphotericin B
1
2014
29
0.110
 Why?
Recombinant Proteins
1
2017
1284
0.110
 Why?
Follow-Up Studies
5
2015
4898
0.110
 Why?
Insurance, Health, Reimbursement
1
2014
96
0.110
 Why?
Immunoconjugates
1
2015
101
0.110
 Why?
Drug Prescriptions
1
2015
250
0.110
 Why?
Constipation
1
2014
89
0.110
 Why?
Pulmonary Disease, Chronic Obstructive
2
2011
950
0.110
 Why?
China
1
2014
191
0.110
 Why?
Mycoses
1
2014
70
0.110
 Why?
Models, Theoretical
1
2017
546
0.110
 Why?
Morpholines
1
2014
125
0.110
 Why?
ErbB Receptors
2
2016
601
0.110
 Why?
Thiophenes
1
2014
119
0.110
 Why?
Recovery of Function
1
2017
643
0.100
 Why?
Pyridines
1
2016
469
0.100
 Why?
Hodgkin Disease
1
2015
134
0.100
 Why?
Budgets
1
2012
14
0.100
 Why?
Warfarin
1
2014
147
0.100
 Why?
Drug Combinations
2
2011
323
0.100
 Why?
Allopurinol
1
2012
61
0.100
 Why?
Multivariate Analysis
4
2015
1494
0.100
 Why?
Adalimumab
5
2011
44
0.100
 Why?
Laparoscopy
1
2017
454
0.100
 Why?
Gastrointestinal Diseases
1
2014
197
0.100
 Why?
Health Status
2
2008
751
0.100
 Why?
Lisdexamfetamine Dimesylate
1
2012
9
0.100
 Why?
Databases as Topic
2
2009
62
0.100
 Why?
Immunocompromised Host
1
2014
195
0.100
 Why?
Neoplasm Staging
1
2015
1288
0.100
 Why?
Estradiol
1
2015
497
0.100
 Why?
Multiple Sclerosis
1
2017
434
0.090
 Why?
Patient Readmission
1
2017
664
0.090
 Why?
Rivaroxaban
1
2014
254
0.090
 Why?
Sulfonylurea Compounds
1
2012
47
0.090
 Why?
Medicaid
2
2006
437
0.090
 Why?
Sirolimus
1
2012
189
0.090
 Why?
Fractures, Spontaneous
1
2011
13
0.090
 Why?
Spinal Cord Compression
1
2011
19
0.090
 Why?
Hypercalcemia
1
2011
19
0.090
 Why?
Models, Statistical
2
2012
625
0.090
 Why?
Cost Sharing
1
2011
15
0.090
 Why?
Communication
1
2017
838
0.090
 Why?
Efficiency
2
2011
95
0.090
 Why?
Japan
2
2021
98
0.090
 Why?
Bone Diseases, Metabolic
1
2011
60
0.090
 Why?
Antidepressive Agents, Second-Generation
1
2010
43
0.090
 Why?
Bone Neoplasms
1
2012
229
0.090
 Why?
Bronchodilator Agents
1
2011
245
0.080
 Why?
Severity of Illness Index
4
2012
2736
0.080
 Why?
Angiogenesis Inhibitors
1
2011
216
0.080
 Why?
Administration, Oral
1
2012
757
0.080
 Why?
Linear Models
1
2012
816
0.080
 Why?
Gastrointestinal Agents
1
2009
60
0.080
 Why?
Surveys and Questionnaires
3
2021
5346
0.080
 Why?
Antidepressive Agents
1
2011
221
0.080
 Why?
Obesity
1
2022
2860
0.080
 Why?
Etanercept
1
2008
58
0.080
 Why?
Case-Control Studies
2
2014
3326
0.080
 Why?
Blood Chemical Analysis
1
2009
96
0.080
 Why?
Time Factors
2
2017
6503
0.080
 Why?
Age Distribution
3
2015
376
0.070
 Why?
Receptors, Tumor Necrosis Factor
1
2008
162
0.070
 Why?
Employment
2
2007
167
0.070
 Why?
Clinical Trials as Topic
1
2012
998
0.070
 Why?
Digestive System Surgical Procedures
1
2008
98
0.070
 Why?
Quality-Adjusted Life Years
2
2022
108
0.070
 Why?
Veterans Disability Claims
1
2006
1
0.070
 Why?
Private Sector
1
2006
51
0.070
 Why?
Health Benefit Plans, Employee
1
2006
23
0.070
 Why?
Ischemic Attack, Transient
1
2006
60
0.060
 Why?
Child
4
2020
20721
0.060
 Why?
Employer Health Costs
1
2005
4
0.060
 Why?
Coronary Disease
1
2008
384
0.060
 Why?
Metabolic Diseases
1
2007
106
0.060
 Why?
Hallucinations
1
2005
30
0.060
 Why?
Cohort Studies
2
2012
5369
0.060
 Why?
Area Under Curve
1
2005
281
0.060
 Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
236
0.060
 Why?
Carcinoma, Non-Small-Cell Lung
1
2012
1044
0.060
 Why?
Metabolic Syndrome
1
2007
340
0.060
 Why?
Adrenal Cortex Hormones
1
2007
518
0.050
 Why?
Colorectal Neoplasms
1
2011
753
0.050
 Why?
Age Factors
2
2015
3117
0.050
 Why?
Data Collection
1
2006
649
0.050
 Why?
Asthma
2
2007
2215
0.050
 Why?
Psychiatric Status Rating Scales
1
2005
523
0.050
 Why?
Lung
1
2015
3741
0.050
 Why?
Drug Resistance, Neoplasm
1
2007
749
0.050
 Why?
Anti-Asthmatic Agents
1
2006
372
0.050
 Why?
Health Policy
1
2005
353
0.050
 Why?
Interviews as Topic
1
2005
705
0.050
 Why?
Glucagon-Like Peptides
1
2022
51
0.050
 Why?
Mental Health Services
1
2005
399
0.040
 Why?
Double-Blind Method
3
2011
1860
0.040
 Why?
Asia
1
2019
58
0.040
 Why?
Incidence
1
2006
2619
0.040
 Why?
Administration, Inhalation
2
2011
664
0.040
 Why?
Disease Progression
2
2015
2603
0.040
 Why?
Potassium Channel Blockers
1
2017
35
0.040
 Why?
Disease Management
2
2015
588
0.030
 Why?
Models, Econometric
1
2016
34
0.030
 Why?
Itraconazole
1
2016
7
0.030
 Why?
Delayed-Action Preparations
1
2017
176
0.030
 Why?
B-Lymphocytes
1
2020
820
0.030
 Why?
Utilization Review
1
2014
37
0.030
 Why?
Cardiovascular Diseases
1
2007
2018
0.030
 Why?
Early Diagnosis
1
2015
236
0.030
 Why?
Dose-Response Relationship, Drug
2
2009
1943
0.030
 Why?
Aspergillus
1
2014
16
0.030
 Why?
Hypothyroidism
1
2014
71
0.030
 Why?
Cryptococcus
1
2014
8
0.030
 Why?
Forced Expiratory Volume
1
2015
509
0.030
 Why?
Anemia, Iron-Deficiency
1
2014
57
0.030
 Why?
Peripheral Vascular Diseases
1
2014
104
0.030
 Why?
Mood Disorders
1
2014
118
0.030
 Why?
Acute Disease
1
2015
968
0.030
 Why?
Biopsy
1
2015
1085
0.020
 Why?
Risk
1
2014
852
0.020
 Why?
Molecular Targeted Therapy
1
2015
387
0.020
 Why?
Nervous System Diseases
1
2014
251
0.020
 Why?
Matched-Pair Analysis
1
2011
43
0.020
 Why?
Cetuximab
1
2011
94
0.020
 Why?
Critical Care
1
2015
544
0.020
 Why?
Bevacizumab
1
2011
131
0.020
 Why?
Tablets
1
2010
37
0.020
 Why?
Length of Stay
1
2015
1121
0.020
 Why?
State Medicine
1
2009
20
0.020
 Why?
Epidemiologic Methods
1
2009
74
0.020
 Why?
United Kingdom
1
2009
256
0.020
 Why?
Sex Factors
1
2015
1949
0.020
 Why?
Remission Induction
1
2009
269
0.020
 Why?
Injections, Subcutaneous
1
2009
145
0.020
 Why?
Insurance Coverage
1
2010
222
0.020
 Why?
Maximum Tolerated Dose
1
2009
193
0.020
 Why?
Odds Ratio
1
2011
1022
0.020
 Why?
Europe
1
2009
362
0.020
 Why?
Probability
1
2009
308
0.020
 Why?
Statistics, Nonparametric
1
2009
423
0.020
 Why?
Canada
1
2009
345
0.020
 Why?
Confidence Intervals
1
2008
318
0.020
 Why?
Reference Values
1
2009
780
0.020
 Why?
Sex Distribution
1
2008
359
0.020
 Why?
Longitudinal Studies
1
2014
2697
0.020
 Why?
Prognosis
1
2015
3780
0.020
 Why?
Models, Biological
1
2014
1693
0.020
 Why?
Randomized Controlled Trials as Topic
1
2012
1358
0.020
 Why?
Tomography, X-Ray Computed
1
2015
2521
0.020
 Why?
Health Status Disparities
1
2008
248
0.020
 Why?
Infant
2
2007
8913
0.010
 Why?
Child, Preschool
2
2007
10373
0.010
 Why?
Emergency Medical Services
1
2007
548
0.010
 Why?
Risk Assessment
1
2009
3256
0.010
 Why?
Body Mass Index
1
2007
2262
0.010
 Why?
Infant, Newborn
1
2006
5687
0.010
 Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (357) concept(s)
_
Co-Authors Expand Description
See all (2) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)